Clinical Trials Browser

Phase 1 × Interventional × poly ICLC × Clear all

NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT05111353 2026-05-06

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT05283109 2026-04-30

ETAPA I

Phase 1 Active not recruiting

24 enrolled 9 charts

Glioblastoma, Glioma

NCT02287428 2026-04-17

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase 1 Active not recruiting

Glioblastoma

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Phase 1 Active not recruiting

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Phase 1 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

8 enrolled 9 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06529822 2026-01-13

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Phase 1 Recruiting

Urinary Bladder Neoplasms

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT05010200 2026-01-07

PGV-Prostate

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT01970358 2025-12-29

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Phase 1 Completed

15 enrolled 8 charts

Melanoma

NCT06411691 2025-12-18

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Phase 1 Recruiting

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04117087 2025-12-03

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04248569 2025-12-03

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Phase 1 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT05013216 2025-12-03

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03223103 2025-09-10

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Phase 1 Active not recruiting

Brain Neoplasms, Glioblastoma, Neoplasms

NCT04201873 2025-08-22

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Phase 1 Active not recruiting

Glioblastoma

NCT04116320 2025-07-14

AM-003

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT05025488 2025-04-06

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Phase 1 Recruiting

Thrombocythemia, Essential, Primary Myelofibrosis

NCT03956056 2024-07-17

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Phase 1 Terminated

12 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Phase 1 Terminated

14 enrolled 10 charts

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

NCT03835533 2024-04-12

PORTER

Phase 1 Completed

43 enrolled 19 charts

Metastatic Castration-resistant Prostate Cancer

NCT03121677 2023-08-14

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Phase 1 Terminated

Lymphoma, Follicular

NCT03359239 2023-05-16

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Phase 1 Completed

Urologic Neoplasms

NCT04799431 2023-05-09

Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Phase 1 Withdrawn

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms

NCT00616941 2022-10-12

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Completed

28 enrolled 16 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Phase 1 Terminated

8 enrolled 16 charts

Melanoma, Neoplasms

NCT03262103 2022-09-10

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT01834248 2022-07-22

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05281926 2022-03-16

A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients

Phase 1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02427581 2022-03-10

Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT03422094 2021-10-27

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Phase 1 Terminated

Glioblastoma

NCT02544880 2021-06-15

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03068832 2021-05-25

Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

Phase 1 Withdrawn

Pediatric Brain Tumor

NCT03380871 2021-02-26

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Phase 1 Completed

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Phase 1 Completed

Neoplasms

NCT03162562 2020-12-22

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Phase 1 Terminated

Ovarian Neoplasms

NCT03597282 2020-09-03

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Phase 1 Terminated

Melanoma

NCT01532960 2020-05-08

Breast 41

Phase 1 Terminated

Breast Neoplasms

NCT02452775 2020-04-24

Autologous OC-L Vaccine and Ovarian Cancer

Phase 1 Terminated

Fallopian Tube Neoplasms

NCT02947854 2019-08-28

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

Phase 1 Completed

Healthy Volunteer

NCT03166254 2019-04-12

Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02061449 2018-12-24

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

Phase 1 Terminated

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT02149225 2018-08-07

GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients

Phase 1 Completed

Glioblastoma

NCT02510950 2017-11-17

Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

Phase 1 Terminated

Glioblastoma